Label free phosphate functionalized semiconducting polymer dots for detection of iron(III) and cytochrome c with application to apoptosis imaging

We report on facile synthesis and characterization of phosphate-functionalized polymer dots (PDs) by doping tributyl phosphate (TBP) in a semiconducting polymer poly[9,9-dioctylfluorenyl-2,7-diyl)-co-1,4-benzo-{2,10-3}-thiadiazole)] (PFBT). Then, the prepared TBP@PFBT PDs were used to develop a very high sensitive probe for detection Fe3+, Cu2+ ions and Cytochrome c based on aggregation induced fluorescence off mechanism. The PDs exhibited a linear dynamic range for Fe3+ from 0.1 to 2 nM with a detection limit of 30 pM and for Cu2+ from 2.0 to 50.0 nM with a detection limit of 0.35 nM. Meanwhile, this probe showed a linear dynamic range for Cyt c from 175 to 1750 pM with a detection limit of 32.7 pM. The TBP@PFBT PDs is a simple, one-step, fast, non-invasive, label-free, and inexpensive probe that is capable of online apoptosis monitoring response to drugs with an ever-present opportunity to contribute in a variety of in-vitro and in-vivo biological applications. We also obtained sharp, specific 2D and 3D imaging results for early stage apoptosis in breast cancer cells. Moreover, this technique possesses the advantage of rapid determination of Fe3+ ion in biological or environmental samples. Importantly, this label-free assay provides short determination time of only a few min, easy operation and very low LOD allowing 100–4000 times increased in sensitivity over previously reported probes, together with high selectivity without need to using biorecognition element...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research

Related Links:

Publication date: Available online 25 June 2019Source: Meta GeneAuthor(s): Roby Will Vencatto, Susana Ramalho, Fernando Augusto Lima Marson, Luciana Montes Rezende, Stéphanie Villa-Nova Pereira, Luciana Cardoso Bonadia, Carmen Silvia Passos Lima, Carmen Silvia BertuzzoAbstractBreast cancer (BC) is the second most prevalent type of cancer worldwide and the most common among women. Also, BC shows different subtypes and patterns of chemotherapy response. Moreover, BC recurrence pattern is not well knowledge. But, genetic variants can alter drug pharmacokinetics and pharmacodynamics with an impact in treatment outcome. ...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 24 June 2019Source: European UrologyAuthor(s): Yu Wei, Junlong Wu, Weijie Gu, Xiaojian Qin, Bo Dai, Guowen Lin, Hualei Gan, Stephen J. Freedland, Yao Zhu, Dingwei YeAbstractGenetic testing for prostate cancer (PCa) patients is in constant development. Specific genetic alterations indicate personalized managing strategies, requiring clinicians to refer appropriate patients for genetic testing. However, our understanding of genetic epidemiology of PCa is mainly based on data from Caucasian populations. In addition, there is evidence that alterations in DNA repair genes (DRGs) may be ethnic ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsTo our knowledge, this is the largest study to date detailing the comorbidities associated with LE and LE treatment rates within each. Our findings suggest that a sizable proportion of cancer-related LE patients do not receive appropriate treatment. Furthermore, this study highlights the role of advanced venous disease as an LE comorbidity that is frequently untreated and its associated gap in treatment.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
ConclusionsSupplemental training helps radiologists improve their screening performance, despite the mainly moderate quality of the studies. There is a need for better designed studies. Future studies should focus on performance in actual screening practice and should look for methods to isolate the training effect. If test sets are used, focus should be on knowledge about correlation between performance on test sets and actual screening practice.
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Condition:   Metastatic Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: Treatment of physician's choice;   Drug: vinorelbine Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer Female;   Dysphagia;   Adjuvant Radiotherapy Intervention:   Device: Hepilor Sponsor:   Cynthia Aristei Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionEIBR results in acceptable QoL and surgical results. In patients with a prior RT, QoL is significantly lower and surgical results are significantly worse. However, high acceptance rates suggest EIBR being a justifiable option even for this group. Prospective studies and long-term follow-up are required for definitive conclusions.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
ConclusionAlmost all patients with ILRR were operated. Especially patients with hormone receptor-negative recurrent breast cancer seemed to show a benefit having been treated with chemotherapy. Most patients were without recurrence after their particular therapies.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
Study found low levels of alcohol (AC) health literacy and numeracy. In 205 women and 33 NHS staff, AC was identified as breast cancer (BC) risk factor by 19.5% and 48.5%, respectively.Both groups had concerns about how to talk about AC and BC risk factors in non-stigmatising way
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Authors: Ding W, Li D, Zhang P, Shi L, Dai H, Li Y, Bao X, Wang Y, Zhang H, Deng L Abstract Breast cancer is a highly heterogeneous disease and numerous secreted factors may differentially contribute to a macrophage phenotype whose extensive infiltration is generally regarded as indicative of an unfavorable outcome. How different breast tumor cells and macrophage cells interplay or influence each other on the alternative splicing (AS) level have not been characterized. Here, we exploited one previous study, which investigated the interplay between macrophages and estrogen receptor‑positive (ER+) breast cancer and...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Environmental Health | Iron